Inlexzo is a drug owned by Janssen Biotech Inc. It is protected by 6 US drug patents filed from 2025 to 2026 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Nov 07, 2038. Details of Inlexzo's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US12636300 | Methods Of Treatment And Maintenance Therapy For Bladder Cancer Using Gemcitabine |
Nov, 2038
(12 years from now) | Active |
| US10729823 | Multi-Unit Drug Delivery Devices And Methods |
Aug, 2034
(7 years from now) | Active |
| US12447241 | Multi-Unit Drug Delivery Devices And Methods |
Aug, 2034
(7 years from now) | Active |
| US8679094 | Implantable Device With Intravesical Tolerability And Methods Of Treatment |
Apr, 2032
(5 years from now) | Active |
| US12576253 | Drug Delivery Device With Intravesical Tolerability |
Dec, 2030
(4 years from now) | Active |
| US12403086 | Solid Drug Tablets For Implantable Drug Delivery Devices |
Jun, 2030
(3 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Inlexzo's patents.
Latest Legal Activities on Inlexzo's Patents
Given below is the list of recent legal activities going on the following patents of Inlexzo.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Recordation of Patent Grant Mailed | 28 Oct, 2025 | US12447241 |
| Email Notification | 21 Oct, 2025 | US12447241 |
| Mail Patent eGrant Notification | 21 Oct, 2025 | US12447241 |
| Patent Issue Date Used in PTA Calculation | 21 Oct, 2025 | US12447241 |
| Patent eGrant Notification | 21 Oct, 2025 | US12447241 |
| Recordation of Patent eGrant | 21 Oct, 2025 | US12447241 |
| Email Notification | 09 Oct, 2025 | US12447241 |
| Issue Notification Mailed | 08 Oct, 2025 | US12447241 |
| Dispatch to FDC | 01 Oct, 2025 | US12447241 |
| Application Is Considered Ready for Issue | 01 Oct, 2025 | US12447241 |
FDA has granted several exclusivities to Inlexzo. Till the time
these exclusivities
are active, no other company can market a generic or bioequivalent version of Inlexzo, regardless of the status of it's patents. These exclusivities hence play a crucial role in
delaying the generic
launch. Given below are details of the exclusivities granted to
Inlexzo.
Exclusivity Information
Inlexzo holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2028. Details of Inlexzo's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 09, 2028 |
US patents provide insights into the exclusivity only within the United States, but
Inlexzo is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Inlexzo's family patents as well as insights into
ongoing legal events
on those patents.
Inlexzo's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Inlexzo:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
Generic Launch
Generic Release Date:
Inlexzo's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Nov 07, 2038 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Inlexzo Generic API suppliers:
Gemcitabine Hydrochloride is the generic name for the brand Inlexzo. 25 different companies have already filed for the generic of Inlexzo, with Adaptis having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Inlexzo's generic
Alternative Brands for Inlexzo
There are several other brand drugs using the same active ingredient (Gemcitabine Hydrochloride) as Inlexzo. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
Apart from brand drugs containing the same ingredient, some generics have also been filed for Gemcitabine Hydrochloride, Inlexzo's active ingredient. Check the complete list of approved generic manufacturers for Inlexzo
About Inlexzo
Inlexzo is a drug owned by Janssen Biotech Inc. Inlexzo uses Gemcitabine Hydrochloride as an active ingredient. Inlexzo was launched by Janssen in 2025.
Approval Date:
Inlexzo was approved by FDA for market use on 09 September, 2025.
Active Ingredient:
Inlexzo uses Gemcitabine Hydrochloride as the active ingredient. Check out other Drugs and Companies using Gemcitabine Hydrochloride ingredient
Dosage:
Inlexzo is available in system form for intravesical use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 225MG BASE | SYSTEM | Prescription | INTRAVESICAL |